VIPR1 and neurodegenerative disease: VPAC1 receptor modulation of microglial phenotype to support hippocampal neurogenesis may therefore be of therapeutic relevance to conditions combining cognitive decline and neuro-inflammation such as temporal lobe epilepsy, Alzheimer's, and other neurodegenerative diseases.